{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+erythropoietin",
    "query": {
      "intervention": "Low dose erythropoietin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+erythropoietin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T08:46:37.051Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07422480",
      "title": "A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Elritercept",
          "type": "DRUG"
        },
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-05-21",
      "completion_date": "2033-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 31,
      "location_summary": "Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07422480"
    },
    {
      "nct_id": "NCT00589953",
      "title": "High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infant, Premature",
        "Erythropoietin",
        "Brain Injury",
        "Intraventricular Hemorrhage",
        "Periventricular Leukomalacia",
        "Neurodevelopmental Outcomes",
        "Randomized Clinical Trial"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atlantic Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Hours",
        "sex": "ALL",
        "summary": "Up to 24 Hours"
      },
      "enrollment_count": 22,
      "start_date": "2007-07",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-30",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 1,
      "location_summary": "Morristown, New Jersey",
      "locations": [
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589953"
    },
    {
      "nct_id": "NCT00379912",
      "title": "Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (Monotherapy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Larry Cripe, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2006-09",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2018-02-14",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 9,
      "location_summary": "Galesburg, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 4 more",
      "locations": [
        {
          "city": "Galesburg",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00379912"
    },
    {
      "nct_id": "NCT03277183",
      "title": "Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anemia",
        "CKD",
        "Atherosclerosis",
        "Cardiovascular"
      ],
      "interventions": [
        {
          "name": "Low dose erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "High dose erythropoietin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2017-11-02",
      "completion_date": "2019-06-03",
      "has_results": true,
      "last_update_posted_date": "2020-08-13",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03277183"
    },
    {
      "nct_id": "NCT04707768",
      "title": "Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia Associated With Chronic Kidney Disease (CKD)"
      ],
      "interventions": [
        {
          "name": "Vadadustat",
          "type": "DRUG"
        },
        {
          "name": "Mircera®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 456,
      "start_date": "2021-06-18",
      "completion_date": "2023-01-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 58,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04707768"
    },
    {
      "nct_id": "NCT05340465",
      "title": "Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prematurity",
        "Iron-deficiency",
        "Iron Deficiency Anemia",
        "Iron Malabsorption"
      ],
      "interventions": [
        {
          "name": "Darbepoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Low Molecular Weight Iron Dextran",
          "type": "DRUG"
        },
        {
          "name": "Ferumoxytol injection",
          "type": "DRUG"
        },
        {
          "name": "Oral iron supplements",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "3 Days",
        "sex": "ALL",
        "summary": "Up to 3 Days"
      },
      "enrollment_count": 120,
      "start_date": "2022-11-27",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05340465"
    },
    {
      "nct_id": "NCT03263091",
      "title": "Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Roxadustat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2018-01-29",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-08-01",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 30,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03263091"
    },
    {
      "nct_id": "NCT00910858",
      "title": "A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human erythropoietin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-01",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910858"
    },
    {
      "nct_id": "NCT00071799",
      "title": "A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Physician Choice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2003-11-01",
      "completion_date": "2007-07-01",
      "has_results": true,
      "last_update_posted_date": "2019-10-29",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071799"
    },
    {
      "nct_id": "NCT03682536",
      "title": "A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Luspatercept",
          "type": "DRUG"
        },
        {
          "name": "Epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 363,
      "start_date": "2019-01-02",
      "completion_date": "2027-09-28",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-09-29T08:46:37.051Z",
      "location_count": 25,
      "location_summary": "Berkeley, California • San Diego, California • Whittier, California + 22 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682536"
    }
  ]
}